26 May 2023 - Recommendation based on results from the Phase 3 CheckMate-816 trial, in which Opdivo with chemotherapy demonstrated improved ...
26 May 2023 - Priority review granted with PDUFA action date of 25 November 2023. ...
25 May 2023 - PDUFA target action date set for 30 November 2023. ...
25 May 2023 - Application to the EMA is supported by data from the Phase 3 CARTITUDE-4 study, which evaluated the ...
25 May 2023 - First FLT3 inhibitor approved in newly diagnosed setting based on QuANTUM-First results demonstrating Vanflyta added to ...
25 May 2023 - Australians battling prostate cancer that has spread past the prostate will soon benefit from subsidised medicine ...
24 May 2023 - The pCPA agreement will support the public listings and reimbursement of Xpovio. ...
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...
22 May 2023 - The system visually highlights cancer that may have otherwise been left behind and is designed to be ...
22 May 2023 - Approval based on the positive PIONEER trial, in which once-daily Ayvakit achieved significant improvements in disease symptoms ...
18 May 2023 - This study aimed to assess whether there have been changes in the quality of clinical evidence ...
19 May 2023 - Today, the FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab) for relapsed or refractory diffuse large ...
17 May 2023 - Elevar Therapeutics today announced it submitted a new drug application to the US FDA for its investigational ...
17 May 2023 - A worrisome scarcity of cancer drugs has heightened concerns about the troubled generic drug industry. ...
16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer ...